Get started
Author

Alessandro Galbiati

Observed names: A. Galbiati, GALBIATI, ALESSANDRO
ORCID: 0000-0002-8795-7934
Observed ORCID: 0000-0002-8795-7934
OpenAlex ID: A5068251997
Functional transcription promoters at DNA double-strand breaks mediate RNA-driven phase separation of damage-response factors
2019 · Fabio Pessina, Fabio Giavazzi, et al. · Nature Cell Biology · 376
A damaged genome’s transcriptional landscape through multilayered expression profiling around in situ-mapped DNA double-strand breaks
2017 · Fabio Iannelli, Alessandro Galbiati, et al. · Nature Communications · 134
PDF
Interplays between ATM/Tel1 and ATR/Mec1 in sensing and signaling DNA double-strand breaks
2013 · Elisa Gobbini, Daniele Cesena, et al. · DNA repair · 108
A novel single-cell method provides direct evidence of persistent DNA damage in senescent cells and aged mammalian tissues
2017 · Alessandro Galbiati, Christian Beauséjour, et al. · Aging Cell · 83
PDF
MRE11-RAD50-NBS1 Complex Is Sufficient to Promote Transcription by RNA Polymerase II at Double-Strand Breaks by Melting DNA Ends
2021 · Sheetal Sharma, Roopesh Anand, et al. · Cell Reports · 76
PDF
Mec1/ATR regulates the generation of single‐stranded DNA that attenuates Tel1/ATM signaling at DNA ends
2013 · Michela Clerici, Camilla Trovesi, et al. · The EMBO Journal · 73
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
2021 · Francesca Bizzaro, Ilaria Fuso Nerini, et al. · Journal of Hematology & Oncology · 63
PDF
Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta
2022 · Martin L. Stockley, Amanda Ferdinand, et al. · Journal of Medicinal Chemistry · 53
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
2023 · Gonzalo Rodriguez-Berriguete, Marco Ranzani, et al. · Clinical Cancer Research · 44
PDF
Recent Advancements in DNA Damage–Transcription Crosstalk and High-Resolution Mapping of DNA Breaks
2017 · Valerio Vitelli, Alessandro Galbiati, et al. · Annual Review of Genomics and Human Genetics · 41
Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition
2022 · Kunzah Jamal, Alessandro Galbiati, et al. · Cancer Research Communications · 30
PDF
DROSHA is recruited to DNA damage sites by the MRN complex to promote non-homologous end joining
2021 · Matteo Cabrini, Marco Roncador, et al. · Journal of Cell Science · 23
PDF
Quantitative, titratable and high-throughput reporter assays to measure DNA double strand break repair activity in cells
2023 · Eeson Rajendra, Diego Grande, et al. · Nucleic Acids Research · 19
PDF
DNA Damage In Situ Ligation Followed by Proximity Ligation Assay (DI-PLA)
2018 · Alessandro Galbiati, Fabrizio d’Adda di Fagagna · Methods in molecular biology · 18
Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy
2025 · Eeson Rajendra, Claudio A Lademann, et al. · Nucleic Acids Research · 7
Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 Inhibitor
2025 · Sam E. Mann, Julien Lefranc, et al. · Journal of Medicinal Chemistry · 7
Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair
2025 · Giuditta Illuzzi, Alessandro Galbiati, et al. · NAR Cancer · 6
PDF
Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1
2025 · Sam E. Mann, Owen A. Davis, et al. · Journal of Medicinal Chemistry · 4
The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
2026 · Helen M.R. Robinson, Vera Grinkevich, et al. · Clinical Cancer Research · 2
Abstract 2905: Combination of the ATR inhibitor, ART0380, with irinotecan for treating ATM-negative tumors
2025 · Helen M. Robinson, Desiree Piscitello, et al. · Cancer Research · 2
139 (PB127): ART6043: a first-in-class clinical DNA Polymerase Theta polymerase domain inhibitor for potentiating PARP inhibitor efficacy
2024 · H. Robinson, V. Grinkevich, et al. · European Journal of Cancer · 1
Abstract LB222: Elucidating the cellular responses and mechanism of action of 177Lu-based radioligand therapy
2024 · Marco Ranzani, Sravanth Hindupur, et al. · Cancer Research · 1
Correction to “Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta”
2023 · Martin L. Stockley, Giovanni Benedetti, et al. · Journal of Medicinal Chemistry · 1
PDF
Protein Folding Interference Enables Selective Cyclin D1 Degradation
2026 · Alessandro Galbiati, Enrica Colasurdo, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Data from The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
2026 · Helen M.R. Robinson, Vera Grinkevich, et al.
Works count: 73
Citation count: 1,172
H-index: 14
I10-index: 14
Year
Topic
Type